Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Our analysis revealed that palbociclib showed a higher risk of hematologic toxicity. Ribociclib showed higher risks of hepatotoxicity, nephrotoxicity, and QT prolongation. Abemaciclib showed higher risks of hepatotoxicity, gastrointestinal effects, interstitial lung disease, and thrombosis. These findings provide valuable insights for CDK4/6 inhibitor selection.
Authors
- Wei Zhuang (ORCID: https://orcid.org/0000-0002-1720-8882)
- Yanbin Zeng
- Lizhu Weng (ORCID: https://orcid.org/0000-0003-0188-8614)
- Jianhui Yang (ORCID: https://orcid.org/0000-0002-8710-1722)
- Wanlong Lin
Institutions
- Xiamen University (CN)
- Children’s Hospital of Fudan University Xiamen Branch (CN)
- Xiamen Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1186/s40360-024-00770-6
- Citations
- 29
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Natural Science Foundation of Xiamen City
- National Natural Science Foundation of China